EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies
出版年份 2022 全文链接
标题
EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies
作者
关键词
-
出版物
Cancers
Volume 14, Issue 19, Pages 4761
出版商
MDPI AG
发表日期
2022-09-30
DOI
10.3390/cancers14194761
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy
- (2022) Shanshan Sun et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2
- (2022) XueHui Liu et al. CELL CYCLE
- Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress
- (2022) Yiji Liao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation
- (2022) Liyuan Wang et al. Nature Communications
- Editorial: Combinatorial Approaches for Cancer Treatment: From Basic to Translational Research
- (2022) Aniello Cerrato et al. Frontiers in Oncology
- Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
- (2022) Mengdi Song et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation
- (2022) Lin Zhang et al. Nature Communications
- Inhibition of polycomb repressive complex 2 by targeting EED protects against cisplatin‐induced acute kidney injury
- (2022) Chao Yu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy
- (2022) Cheng Qian et al. PHARMACOLOGICAL RESEARCH
- Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer
- (2022) Daniel Sanghoon Shin et al. SEMINARS IN ONCOLOGY
- Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
- (2021) Daolu Yang et al. Molecular Therapy-Nucleic Acids
- Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells
- (2021) Yingzi Zhang et al. Breast Cancer
- Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2
- (2021) Taohui Zeng et al. Biomed Research International
- A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer
- (2021) Xuan Deng et al. Cell Death & Disease
- TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
- (2021) Sha Zhou et al. Cell Death & Disease
- Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors
- (2021) Chen Li et al. Clinical Epigenetics
- Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
- (2021) Hon Yan Kelvin Yip et al. Cells
- Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers
- (2021) Yuzuka Kanno et al. Frontiers in Oncology
- An EZH2‐dependent transcriptional complex promotes aberrant epithelial remodelling after injury
- (2021) Huy Q Le et al. EMBO REPORTS
- Going beyond Polycomb: EZH2 functions in prostate cancer
- (2021) Su H. Park et al. ONCOGENE
- Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer
- (2021) Chanchan Gao et al. MEDICAL SCIENCE MONITOR
- Selective EZH2 inhibitor zld1039 alleviates inflammation in cisplatin-induced acute kidney injury partially by enhancing RKIP and suppressing NF-κB p65 pathway
- (2021) Li Wen et al. ACTA PHARMACOLOGICA SINICA
- An SETD1A/Wnt/β-catenin feedback loop promotes NSCLC development
- (2021) Rui Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer
- (2021) Mingkun Zhang et al. Bioengineered
- EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition
- (2020) Sergey Karakashev et al. CANCER CELL
- Cisplatin resistance in gastric cancer cells is involved with GPR30‐mediated epithelial‐mesenchymal transition
- (2020) Xiaofeng Wang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair
- (2020) Allyson E. Koyen et al. ONCOGENE
- EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin
- (2020) Si-qi Chen et al. Cell Division
- The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
- (2020) Jiabei Zhou et al. Frontiers in Pharmacology
- EZH2: a novel target for cancer treatment
- (2020) Ran Duan et al. Journal of Hematology & Oncology
- Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives
- (2020) João Lobo et al. Cancers
- EZH2-Targeted Therapies in Cancer: Hype or a Reality
- (2020) Marie-Lisa Eich et al. CANCER RESEARCH
- Combinatorial drug therapy in cancer - New insights
- (2020) Karanpreet Bhatia et al. LIFE SCIENCES
- In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium
- (2020) Raushan T. Kurmasheva et al. PEDIATRIC BLOOD & CANCER
- EZH2 inhibition: a promising strategy to prevent cancer immune editing
- (2020) Ning Kang et al. Epigenomics
- Post-translational modifications of EZH2 in cancer
- (2020) Zhongwei Li et al. Cell and Bioscience
- Head and neck squamous cell carcinoma
- (2020) Daniel E. Johnson et al. Nature Reviews Disease Primers
- MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers
- (2020) Yue Sun et al. Translational Oncology
- Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
- (2019) Xiaofu Qiu et al. BMC CANCER
- Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin
- (2019) Chao He et al. Clinical Epigenetics
- Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer
- (2019) Swathi Ramakrishnan et al. CELL DEATH AND DIFFERENTIATION
- MUC1-C INTEGRATES CHROMATIN REMODELING AND PARP1 ACTIVITY IN THE DNA DAMAGE RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER CELLS
- (2019) Masaaki Yamamoto et al. CANCER RESEARCH
- EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy
- (2019) Julian Puppe et al. CLINICAL CANCER RESEARCH
- Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide-resistance in castration-resistance prostate cancer
- (2019) Yunfeng Bai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
- (2019) Jason K. Sicklick et al. NATURE MEDICINE
- 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression
- (2019) Jun Ni et al. Cell Death & Disease
- lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer
- (2019) Gan Yu et al. Molecular Therapy-Nucleic Acids
- Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors
- (2019) Ratnakar Singh et al. Cancers
- Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors
- (2019) Timothy A. Yap et al. CLINICAL CANCER RESEARCH
- Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers
- (2019) Liye Zhou et al. CLINICAL CANCER RESEARCH
- New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
- (2019) Shang-Hung Chen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PCAT‐1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2
- (2019) Hui Li et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2
- (2019) Yafei Ye et al. Open Biology
- Clinical and biological significance of EZH2 expression in endometrial cancer
- (2019) Ju-Won Roh et al. CANCER BIOLOGY & THERAPY
- Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
- (2019) Ludovic Fournel et al. CANCER LETTERS
- BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents
- (2019) Arun Kanakkanthara et al. CANCER RESEARCH
- Bon voyage: A transcriptional journey around DNA breaks
- (2019) Pierre Caron et al. DNA REPAIR
- EZH2 loss drives resistance to carboplatin and paclitaxel in serous ovarian cancers expressing ATM
- (2019) Johanna Naskou et al. MOLECULAR CANCER RESEARCH
- EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
- (2019) Dongwei Dou et al. OncoTargets and Therapy
- AFAP1‑AS1 induces cisplatin resistance in non‑small cell lung cancer through PI3K/AKT pathway
- (2019) Yang Liu et al. Oncology Letters
- Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 Noncoding RNA in Ovarian A2780 Cells
- (2018) Zahre Sajadpoor et al. APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
- Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo
- (2018) Chang Yu et al. BIOMATERIALS
- Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation
- (2018) Si Sun et al. CANCER SCIENCE
- STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner
- (2018) Shanshan Sun et al. CLINICAL CANCER RESEARCH
- SREBP2 contributes to cisplatin resistance in ovarian cancer cells
- (2018) Lei Zheng et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity
- (2018) Myriam Koubi et al. NUCLEIC ACIDS RESEARCH
- Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
- (2018) Alison Hirukawa et al. Nature Communications
- miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer
- (2018) Jing Sun et al. ONCOGENE
- TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2
- (2018) Caihui Xu et al. Cell and Bioscience
- MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
- (2017) Peilong Li et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer
- (2017) Shinya Oki et al. Oncotarget
- Effect of wound fluid on chemotherapy sensitivity of T24 bladder cancer cells with different enhancer of zeste homolog 2 status
- (2017) Huan Bi et al. Oncotarget
- Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target
- (2017) Yiping Wen et al. Oncotarget
- Combination therapy in combating cancer
- (2017) Reza Bayat Mokhtari et al. Oncotarget
- Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer
- (2017) Ali R. Özeş et al. Scientific Reports
- BRCA mutation in ovarian cancer: testing, implications and treatment considerations
- (2017) Robert T. Neff et al. Therapeutic Advances in Medical Oncology
- Interfering EZH2 Expression Reverses the Cisplatin Resistance in Human Ovarian Cancer by Inhibiting Autophagy
- (2016) Yang Sun et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer
- (2016) Michela Serresi et al. CANCER CELL
- EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene
- (2016) Yuxiang Huang et al. MOLECULAR CARCINOGENESIS
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity
- (2016) Jae Won Chang et al. ORAL ONCOLOGY
- Cisplatin resistance and opportunities for precision medicine
- (2016) Lauren Amable PHARMACOLOGICAL RESEARCH
- EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis
- (2016) Haidan Liu et al. Oncotarget
- Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background
- (2016) Koraljka Gall Trošelj et al. Clinical Epigenetics
- MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells
- (2016) Ziqiang Zhu et al. PLoS One
- siRNA Silencing EZH2 Reverses Cisplatin-resistance of Human Non-small Cell Lung and Gastric Cancer Cells
- (2015) Wen Zhou et al. Asian Pacific Journal of Cancer Prevention
- EZH2 in Bladder Cancer, a Promising Therapeutic Target
- (2015) Mónica Martínez-Fernández et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes
- (2015) HUALI WANG et al. Molecular Medicine Reports
- EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
- (2015) Christine M. Fillmore et al. NATURE
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression
- (2015) Liqiong Cai et al. TUMOR BIOLOGY
- EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
- (2015) John E. Campbell et al. ACS Medicinal Chemistry Letters
- Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation
- (2015) Yong-Min Choi et al. PLoS One
- VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2-Targeted Therapy
- (2014) E. Riquelme et al. CLINICAL CANCER RESEARCH
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy
- (2014) Chunhua Xu et al. LUNG CANCER
- miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer
- (2014) Lin Liu et al. TUMOR BIOLOGY
- Regulation and Role of EZH2 in Cancer
- (2014) Hirohito Yamaguchi et al. Cancer Research and Treatment
- EZH2: biology, disease and structure-based drug discovery
- (2013) Jin-zhi Tan et al. ACTA PHARMACOLOGICA SINICA
- EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1
- (2013) Tao Li et al. CANCER BIOLOGY & THERAPY
- Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
- (2013) Eunhee Kim et al. CANCER CELL
- Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure
- (2013) Yiping Huang et al. CELL CYCLE
- Repression of Dicer is associated with invasive phenotype and chemoresistance in ovarian cancer
- (2013) YAN KUANG et al. Oncology Letters
- Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin
- (2013) J Cai et al. Oncogenesis
- Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target
- (2013) Hua Li et al. Frontiers in Oncology
- A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
- (2012) C. Simon et al. GENES & DEVELOPMENT
- EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase Complex
- (2012) Ji Min Lee et al. MOLECULAR CELL
- Combinatorial drug therapy for cancer in the post-genomic era
- (2012) Bissan Al-Lazikani et al. NATURE BIOTECHNOLOGY
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
- (2012) Panagiotis Ntziachristos et al. NATURE MEDICINE
- Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
- (2012) C Zeller et al. ONCOGENE
- The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma
- (2012) Jidong Zhang ONCOLOGY REPORTS
- EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling
- (2011) Chun-Ju Chang et al. CANCER CELL
- Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells
- (2011) Y Huang et al. CELL DEATH AND DIFFERENTIATION
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell
- (2011) Wei Yu et al. PLoS One
- Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo
- (2010) Sha Hu et al. CANCER BIOLOGY & THERAPY
- The Molecular Pathogenesis of Head and Neck Cancer
- (2010) Jonah D. Klein et al. CANCER BIOLOGY & THERAPY
- Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2
- (2010) Daisy PF Tsang et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Overexpression of EZH2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia
- (2009) Xin Li et al. AMERICAN JOURNAL OF PATHOLOGY
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
- (2009) W. Fiskus et al. BLOOD
- Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role
- (2009) C William Helm et al. Journal of Ovarian Research
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started